LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.

Trial Details

NCT ID
NCT05990465
Phase
PHASE1
Sponsor
Medical College of Wisconsin
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • Pirtobrutinib
  • LV20.19 CAR T cells
Locations (sample)
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • General inclusion criteria for trial:
  • Patients must be aged ≥18 years and \<81 years with relapsed or refractory B-cell non-Hodgkin Lymphoma (NHL).
  • Diagnosis of relapsed or refractory B-cell NHL including Follicular Lymphoma, Marginal Zone Lymphoma (splenic, nodal, extranodal), Mantle Cell Lymp…
  • Disease specific criteria as follows:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →